Aberrantly expressed long noncoding RNAs as potential prognostic biomarkers in newly diagnosed multiple myeloma: A systemic review and meta-analysis

被引:6
|
作者
Qin, Jiading [1 ,2 ]
Ke, Bo [2 ,3 ]
Liu, Tingting [2 ]
Kong, Chunfang [1 ,2 ]
Li, Anna [2 ]
Fu, Huan [2 ]
Jin, Chenghao [1 ,2 ,3 ]
机构
[1] Nanchang Univ, Med Coll, Nanchang 330006, Jiangxi, Peoples R China
[2] Jiangxi Prov Peoples Hosp, Dept Hematol, Nanchang 330006, Jiangxi, Peoples R China
[3] Soochow Univ, Affiliated Hosp 1, Natl Clin Res Ctr Hematol Dis, Suzhou 215006, Jiangsu, Peoples R China
来源
CANCER MEDICINE | 2023年 / 12卷 / 03期
基金
中国国家自然科学基金;
关键词
clinical prognosis; long noncoding RNA; meta-analysis; multiple myeloma; predictive biomarker; CANCER; RESISTANCE; KNOCKDOWN; TUG1; PVT1; BIAS; H19;
D O I
10.1002/cam4.5135
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Numerous studies have manifested long noncoding RNAs (lncRNAs) as biomarkers to determine the prognosis of multiple myeloma (MM) patients. Nevertheless, the prognostic role of lncRNAs in MM is still ambiguous. Herein, we performed a meta-analysis to evaluate the predictive value of aberrantly expressed lncRNAs in MM. Methods A systemic literature search was performed in PubMed, EMBASE, Cochrane, and Web of Science databases until October 9, 2021, and the protocol was registered in the PROSPERO database (CRD42021284364). Our study extracted the hazard ratios (HRs) and 95% confidence intervals (CIs) of overall survival (OS), progression-free survival (PFS), or event-free survival (EFS). Begg's and Egger's tests were employed to correct publication bias. Result Twenty-six individual studies containing 3501 MM patients were enrolled in this study. The results showed that aberrant expression of lncRNAs was associated with poor OS and PFS of MM patients. The pooled HRs for univariate OS and PFS were 1.48 (95% CI = 1.17-1.88, p < 0.001) and 1.30 (95% CI = 1.18-1.43, p < 0.001), respectively, whereas the pooled HRs for multivariate OS and PFS were 1.50 (95% CI = 1.16-1.95, p < 0.001) and 1.59 (95% CI = 1.22-2.07, p < 0.001), respectively. Subgroup analysis suggested that MALAT1, TCF7, NEAT1, and PVT1 upregulation were associated with poor OS (p < 0.05), PVT1, and TCF7 upregulation were implicated with worse PFS (p < 0.05), while only TCF7 overexpression was correlated with reduced EFS (p < 0.05). Moreover, the contour-enhanced funnel plot demonstrated the reliability of our current conclusion, which was not affected by publication bias. Conclusion Aberrantly expressed particular lncRNAs are critical prognostic indicators in long-term survival as well as promising biomarkers in progression-free status. However, different cutoff values and dissimilar methods to assess lncRNA expression among studies may lead to heterogeneity.
引用
收藏
页码:2199 / 2218
页数:20
相关论文
共 50 条
  • [41] Triplet RVd Induction for Transplant-Eligible Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis
    Guangzhong Yang
    Chuanying Geng
    Yuan Jian
    Huixing Zhou
    Wenming Chen
    Advances in Therapy, 2022, 39 : 3799 - 3834
  • [42] Maintenance Therapy in Newly Diagnosed and Transplant Ineligible Multiple Myeloma Patients: A Meta-Analysis
    Rafae, Abdul
    Jaan, Ali
    Ahmed, Zahoor
    Neupane, Karun
    Ashraf, Sara
    Ali, Sundas
    Khan, Sana Irfan
    Khan, Israr
    Khan, Atif Irfan
    Wahab, Ahsan
    Ali, Rabia
    Saeed, Sara
    Nadeem, Mustafa
    Anwer, Faiz
    BLOOD, 2020, 136
  • [43] Association Between Immunoparesis and Treatment Outcomes of Patients With Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis
    Siwakoti, Ashmita
    Khadka, Sukhdev
    Grimshaw, Alyssa A.
    Giri, Smith
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (11): : e870 - e877
  • [44] Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction A Systematic Review and Meta-analysis
    Dhakal, Binod
    Szabo, Aniko
    Chhabra, Saurabh
    Hamadani, Mehdi
    D'Souza, Anita
    Usmani, Saad Z.
    Sieracki, Rita
    Gyawali, Bishal
    Jackson, Jeffrey L.
    Asimakopoulos, Fotis
    Hari, Parameswaran N.
    JAMA ONCOLOGY, 2018, 4 (03) : 343 - 350
  • [45] Triplet RVd Induction for Transplant-Eligible Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis
    Yang, Guangzhong
    Geng, Chuanying
    Jian, Yuan
    Zhou, Huixing
    Chen, Wenming
    ADVANCES IN THERAPY, 2022, 39 (08) : 3799 - 3834
  • [46] Long noncoding RNAANRIL: a potential novel prognostic marker in cancer A meta-analysis
    Liu, Fang-Teng
    Zhu, Pei-Qian
    Luo, Hong-Liang
    Zhang, Yi
    Hao, Teng-Fei
    Xia, Guang-Fei
    Zhu, Zheng-Ming
    Qiu, Cheng
    MINERVA MEDICA, 2016, 107 (02) : 77 - 83
  • [47] Landscape and clinical significance of long noncoding RNAs involved in multiple myeloma expressed fusion transcripts
    Amundarain, Ane
    Valcarcel, Luis V.
    Ordonez, Raquel
    Garate, Leire
    Miranda, Estibaliz
    Cendoya, Xabier
    Carrasco-Leon, Arantxa
    Calasanz, Maria Jose
    Paiva, Bruno
    Meydan, Cem
    Mason, Christopher E.
    Melnick, Ari
    Rodriguez-Otero, Paula
    Martin-Subero, Jose I.
    San Miguel, Jesus
    Planes, Francisco J.
    Prosper, Felipe
    Agirre, Xabier
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (03) : E113 - E117
  • [48] Noncoding RNAs as a potential biomarker for the prognosis of bladder cancer: a systematic review and meta-analysis
    Jiang, Lan
    Sun, Ge
    Zou, Lina
    Guan, Yue
    Hang, Yongzheng
    Liu, Yanan
    Zhou, Zhiren
    Zhang, Xueqing
    Huang, Xiaojing
    Pan, Hongzhi
    Rong, Shengzhong
    Ma, Hongkun
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2023, : 325 - 334
  • [49] Long noncoding RNAs in bladder cancer prognosis: A meta-analysis
    Zhu, Wei
    Liu, Hailang
    Wang, Xinguang
    Lu, Jinjin
    Yang, Weimin
    PATHOLOGY RESEARCH AND PRACTICE, 2019, 215 (06)
  • [50] Long noncoding RNAs in acute myeloid leukemia: biomarkers, prognostic indicators, and treatment potential
    Farajzadeh, Maryam
    Fathi, Mehrdad
    Jalali, Pooya
    Mahmoudsalehi Kheshti, Armin
    Khodayari, Shahla
    Hojjat-Farsangi, Mohammad
    Jadidi, Farhad
    CANCER CELL INTERNATIONAL, 2025, 25 (01)